Ionis Pharmaceuticals (IONS) Other Non-Current Liabilities (2010 - 2026)

Ionis Pharmaceuticals' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $28.3 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 49.21% year-over-year to $28.3 million in Q1 2026; TTM through Mar 2026 was $28.3 million, a 49.21% decrease from a year earlier, with the FY2025 full-year figure at $28.1 million, down 45.85% from the prior year.
• Other Non-Current Liabilities improved to $28.3 million in Q1 2026 per IONS's latest filing, from $28.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $538.1 million in Q3 2024 and bottomed at $16.4 million in Q2 2023.
• The 4-year median for Other Non-Current Liabilities is $51.9 million (2024), against an average of $187.1 million.
• Across the five-year window, Other Non-Current Liabilities soared 1002.65% in 2024 and slumped 96.36% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $513.7 million in 2023, then plunged by 89.89% to $51.9 million in 2024, then sank by 45.85% to $28.1 million in 2025, then climbed by 0.55% to $28.3 million in 2026.
• Per Business Quant, the three latest IONS Other Non-Current Liabilities figures stand at $28.3 million (Q1 2026), $28.1 million (Q4 2025), and $19.6 million (Q3 2025).